Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8592480 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Jul, 2027
(4 years from now) | |
US9089528 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Jul, 2027
(4 years from now) | |
US8591938 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Feb, 2030
(6 years from now) |
Market Authorisation Date: 18 April, 2011
Treatment: Use of phoslyra for reduction of serum phosphorous in patients
Dosage: SOLUTION;ORAL
5
United States
2
Hong Kong
2
Poland
2
China
2
European Union
1
Russia
1
Japan
1
Brazil
1
South Africa
1
New Zealand
1
Austria
1
Canada
1
Spain
1
Australia
1
Mexico
1
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic